Indivior Pharmaceuticals Inc
NASDAQ:INDV · NASDAQ Global Select
+$0.26 today
Vol 2.82M · Avg 2.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-214.3%
avg 10.9%
ROIC
70.8%
avg 17.6%
ROA
17.4%
avg 4.1%
Analysis
ROIC is currently the strongest return metric at 70.8% versus its period average of 17.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph J. Ciaffoni | Chief Executive Officer & Director | $3.55M | — | 55 | $0.00 | <0.01% |
Patrick A. Barry | Chief Commercial Officer | $2.07M | — | 58 | $0.00 | <0.01% |
Christian Heidbreder | Chief Scientific Officer | $1.49M | — | 63 | $0.00 | <0.01% |
Ryan Preblick | Chief Financial Officer | $1.29M | — | 50 | $0.00 | <0.01% |
Jeffrey W. Burris | Chief Legal Officer | $1.18M | — | 54 | $0.00 | <0.01% |
Jason Thompson | Vice President of Investor Relations | — | — | — | $12,973.00 | 0.01% |
Kevin L. Espinoza | Chief Integrity & Compliance Officer | — | — | — | — | — |
Alice G. Givens | Company Secretary | — | — | 52 | — | — |
Angela Colon-Mahoney | Chief Human Resources Officer | — | — | 50 | — | — |
Vanessa Procter | Executive Vice President of Corporate Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$203,608.49
Sells
2
$2.06M
Net Sentiment
$1.86M
Net selling
Most Active
Ryan Barbara
3 transactions
Analysis
Insiders reported 8 buys worth $203,608.49 and 2 sells worth $2.06M over the last 12 months. That adds up to net selling of $1.86M. Ryan Barbara was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -17.4% | +8.5% (10yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -17.4% over three years. Forward estimates point to Revenue at +8.5% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.75B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.94B
Hinge Health, Inc.
NYSE:HNGE
$5.16B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.13B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.76B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.67B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.58B
Option Care Health, Inc.
NASDAQ:OPCH
$3.47B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.56B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.94B
Who manages INDV?
Indivior Pharmaceuticals Inc (INDV) lists 10 active executives. The top listed executive is Christian Heidbreder, Chief Scientific Officer.
Are INDV insiders buying or selling?
Recent insider activity shows net selling of $7.76M.
Explore More
Continue the stock analysis
Jump to another research area for this company.